Omnicef and Cataract - a phase IV clinical study of FDA data

Summary:

Cataract is reported as a side effect among people who take Omnicef (cefdinir), especially for people who are female, 50-59 old, also take Ambien, and have Pain.

The phase IV clinical study analyzes which people have Cataract when taking Omnicef. It is created by eHealthMe based on reports of 2,586 people who have side effects when taking Omnicef from the FDA, and is updated regularly.

What is Omnicef?

Omnicef has active ingredients of cefdinir. It is often used in sinusitis. eHealthMe is studying from 2,774 Omnicef users. Check the latest studies of Omnicef.

What is Cataract?

Cataract (clouding of the lens inside the eye) is found to be associated with 1,891 drugs and 2,131 conditions by eHealthMe. Check the latest studies of Cataract.

On Jul, 13, 2026

2,586 people reported to have side effects when taking Omnicef.
Among them, 19 people (0.73%) have Cataract.

Among these 19 people:

What is the gender of people who have Cataract when taking Omnicef? *

female: 100 %
male: 0.0 %

What is the age of people who have Cataract when taking Omnicef? *

What are other drugs people take besides Omnicef? *

What are other side effects people have besides Cataract? *

Joint Pain: 19 people, 100.00%
Stress And Anxiety: 19 people, 100.00%
Pain: 18 people, 94.74%
Dizziness: 18 people, 94.74%
Hip Fracture: 17 people, 89.47%
Constipation: 17 people, 89.47%
Bone Pain: 17 people, 89.47%
Headache (pain in head): 17 people, 89.47%
Rashes (redness): 17 people, 89.47%
Mouth Ulcers: 17 people, 89.47%

What are the existing conditions these people have? *

Pain: 17 people, 89.47%
Upper Respiratory Tract Infection: 12 people, 63.16%
Restless Leg Syndrome (a powerful urge to move your legs): 12 people, 63.16%
Muscle Spasms (muscle contraction): 12 people, 63.16%
Multiple Myeloma (cancer of the plasma cells): 12 people, 63.16%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 12 people, 63.16%
Nausea (feeling of having an urge to vomit): 5 people, 26.32%
Constipation: 5 people, 26.32%
Metastases To Bone (cancer spreads to bone): 1 person, 5.26%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Omnicef and have Cataract?

- Check whether Cataract is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Omnicef:

Omnicef (2,774 reports)

Cataract treatments and more:

Cataract (70,565 reports)

Browse all side effects of Omnicef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cataract:

Cataract (1,891 drugs)

Browse all the conditions that are associated with Cataract:

Cataract (2,131 conditions)

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Dsouza MC, "Could risperidone have caused the cataract?: A case report and review of literature", Journal of Research in Psychiatry and Behavioral Science, 2015 Jan .
Dsouza MC, "COULD RISPERIDONE HAVE CAUSED THE CATARACT", JRPBS, 2015 Jan .
Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Dsouza MC, "Could risperidone have caused the cataract?: A case report and review of literature", Journal of Research in Psychiatry and Behavioral Science, 2015 Jan .
Dsouza MC, "COULD RISPERIDONE HAVE CAUSED THE CATARACT", JRPBS, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cefdinir (the active ingredients of Omnicef) and Omnicef (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.